Connect with LRI:
Facebook
Twitter
YouTube
Change.org

Lupus Clinical Trials

New Medical Therapies™

Connective Tissue Diseases

Patient Medical Areas

July 8, 2002

Results from a 24-week, open-label extension of a phase I trial indicate that both dose levels (0.2 mg/kg and 1.0 mg/kg) of BioMarin Pharmaceutical's Aryplase continue to be well tolerated by the five subjects who have received treatment for a total of 48 weeks. Aryplase is an enzyme replacement therapy being developed for the treatment of mucopolysaccharidosis VI. In addition to the positive safety results, the 1.0 mg/kg dose continued to produce a greater sustained reduction than the 0.2 mg/kg dose in the excretion of urinary glycosaminoglycans.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.

Bookmark or share this page with:
  • Delicious
  • Digg
  • StumbleUpon
  • Reddit
  • Facebook